期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
含多黏菌素B抗菌方案治疗多重耐药革兰阴性菌HAP/VAP的贝叶斯网状Meta分析
1
作者 涂超超 周权 +3 位作者 黄玉琴 万冬丽 王汉琴 涂明利 《药物流行病学杂志》 CAS 2023年第4期434-445,共12页
目的采用贝叶斯网状Meta分析方法比较含多黏菌素B的抗菌方案与其他抗菌方案治疗多重耐药革兰阴性菌医院获得性肺炎/呼吸机相关性肺炎(HAP/VAP)的临床疗效。方法计算机检索PubMed、EMbase、The Cochrane Library、Web of Science、CNKI、... 目的采用贝叶斯网状Meta分析方法比较含多黏菌素B的抗菌方案与其他抗菌方案治疗多重耐药革兰阴性菌医院获得性肺炎/呼吸机相关性肺炎(HAP/VAP)的临床疗效。方法计算机检索PubMed、EMbase、The Cochrane Library、Web of Science、CNKI、SinoMed、ChiCTR、WanFang Data和VIP数据库,搜集含多黏菌素B的抗菌方案治疗多重耐药革兰阴性菌HAP/VAP的临床对照研究,检索时限均从建库到2022年10月15日。由2位研究员独立筛选文献、提取资料并评估纳入研究的偏倚风险后,采用Stata 17.0和R 4.1.2软件进行贝叶斯网状Meta分析。结果共纳入1个随机对照试验(RCT)和10项观察性研究,共1385例患者,涉及8种治疗方案。贝叶斯网状Meta分析结果表明,在临床有效率方面,8种用药方案组间差异无统计学意义(P>0.05),累积排序概率曲线下面积(SUCRA)显示多黏菌素B静脉滴注联合多黏菌素B雾化吸入方案的临床有效率高于多黏菌素B静脉滴注单用或其联合替加环素等方案;在病死率方面,文中涉及的4种用药方案中,SUCRA显示多黏菌素B静脉滴注联合多黏菌素B雾化方案的病死率较低,低于多黏菌素B静脉滴注、替加环素单用或两者联用等方案,其中多黏菌素B静脉滴注联合多黏菌素雾化吸入方案的病死率低于多黏菌素B静脉滴注联合替加环素方案,且差异有统计学意义[OR=0.21,95%CrI(0.05,0.94),P<0.05],其余涉及的治疗方案组间差异无统计学意义(P>0.05);在细菌清除率方面,涉及的4种用药方案组间差异无统计学意义(P>0.05)。结论现有证据表明,就生存获益而言,推荐使用多黏菌素B静脉滴注联合多黏菌素B雾化吸入方案治疗多重耐药革兰阴性菌HAP/VAP。受纳入研究数量和质量限制,上述结论尚待更多大样本、高质量、多中心的RCT予以验证。 展开更多
关键词 多黏菌素B 医院获得性肺炎 呼吸机相关性肺炎 多重耐药菌 网状Meta分析
下载PDF
A Selective TRPC3 Inhibitor Pyr3 Attenuates Myocardial Ischemia/Reperfusion Injury in Mice 被引量:3
2
作者 Min LU Xiao-xia FANG +6 位作者 Dan-dan SHI Rui LIU Yan DING Qiu-fang ZHANG han-qin wang Jun-ming TANG Xi-ju HE 《Current Medical Science》 SCIE CAS 2020年第6期1107-1113,共7页
An emerging body of evidence indicates that transient receptor potential TRP channels act as important mediators for a wide variety of physiological functions and are potential targets for drug discovery.Our previous ... An emerging body of evidence indicates that transient receptor potential TRP channels act as important mediators for a wide variety of physiological functions and are potential targets for drug discovery.Our previous study has identified transient receptor potential channel 3(TRPC3)and TRPC6 as cation channels through which most of the damaging calcium enters,aggravates pathological changes in vivo and increases ischemia/reperfusion(I/R)injury in mice.This study aimed to verify the effects of TRPC3 inhibitor Pyr3 on myocardial I/R injury in mice.C57BL/6J wild-type male mice(8 to 12 weeks old)were anesthetized with 3.3%chloral hydrate.A murine I(30 min)/R(24 h)injury model was established by temporary occlusion of the left anterior descending(LAD)coronary artery.Pyr3 was administered at concentrations of 0,2.5,5,or 10 mg/kg via the right jugular vein 5 min before reperfusion.We observed that the selective TRPC3 inhibitor,10 mg/kg Pyr3,significantly decreased the infarct size of left ventricle,and reduced the myocardial cell apoptosis rate and inflammatory response in mice.In a conclusion,TRPC3 can function as a candidate target for I/R injury prevention,and Pyr3 may directly bind to TRPC3 channel protein,inhibit TRPC3 channel activity,and improve TRPC3-related myocardial I/R injury.Pyr3 may be used for clarification of TRPC3 functions and for treatments of TRPC3-mediated diseases. 展开更多
关键词 ischemia/reperfusion injury TRPC3 Pyr3 APOPTOSIS
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部